The Company
Clerio Vision is developing a novel vision correction platform that uses femtosecond lasers for noninvasive vision correction in the human cornea, contact lenses, and intraocular lenses (IOLs). Clerio Vision applies its proprietary Laser Induced Refractive Index Correction (LIRIC) technology to overcome the safety and performance issues with existing refractive surgery, contact lenses, and IOL options. The company has teams in New York, Florida, and California working in research, manufacturing, and sales.
The Partnership
Clerio Vision is led by a management team with a strong history of success. Clerio’s LIRIC platform addresses vision correction in contact lenses, cornea, and intraocular lenses, each having a market size greater than $1B and addressing the vision needs of a vast majority of the population. Clerio Vision’s team includes experts responsible for invention of the first LASIK procedure and former key executives of the leading refractive surgery equipment companies. The founders of Clerio Vision were the co-founders of iCardiac Technologies, a leading provider of cardiac safety testing services to the global pharmaceutical industry. Topmark invested in iCardiac through a legacy fund, and the company was eventually sold to ERT. Having developed a collaborative relationship with the founders over a decade, Topmark co-led Clerio Vision’s initial funding rounds. Working closely with the company, serving on the Board of Directors, Topmark has helped management formally organize the company along three business lines with defined leadership roles and reporting structure. Investing early in accountability and milestone achievement has helped the company successfully attract subsequent financing.